STOKE THERAPEUTICS INC (STOK) Fundamental Analysis & Valuation

NASDAQ:STOK • US86150R1077

Current stock price

33.4 USD
-0.11 (-0.33%)
At close:
33.7 USD
+0.3 (+0.9%)
After Hours:

This STOK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. STOK Profitability Analysis

1.1 Basic Checks

  • In the past year STOK was profitable.
  • STOK had a positive operating cash flow in the past year.
  • STOK had negative earnings in each of the past 5 years.
  • STOK had a negative operating cash flow in each of the past 5 years.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • STOK has a better Return On Assets (11.39%) than 94.03% of its industry peers.
  • STOK has a better Return On Equity (13.32%) than 93.26% of its industry peers.
  • With an excellent Return On Invested Capital value of 6.66%, STOK belongs to the best of the industry, outperforming 91.91% of the companies in the same industry.
Industry RankSector Rank
ROA 11.39%
ROE 13.32%
ROIC 6.66%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • STOK's Profit Margin of 19.96% is amongst the best of the industry. STOK outperforms 93.06% of its industry peers.
  • With an excellent Operating Margin value of 13.06%, STOK belongs to the best of the industry, outperforming 91.14% of the companies in the same industry.
Industry RankSector Rank
OM 13.06%
PM (TTM) 19.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. STOK Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), STOK is destroying value.
  • STOK has more shares outstanding than it did 1 year ago.
  • STOK has more shares outstanding than it did 5 years ago.
  • STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 21.89 indicates that STOK is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 21.89, STOK belongs to the top of the industry, outperforming 90.17% of the companies in the same industry.
  • There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 21.89
ROIC/WACC0.72
WACC9.28%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • STOK has a Current Ratio of 6.53. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.53, STOK is doing good in the industry, outperforming 65.32% of the companies in the same industry.
  • STOK has a Quick Ratio of 6.53. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 6.53, STOK is in the better half of the industry, outperforming 65.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.53
Quick Ratio 6.53
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. STOK Growth Analysis

3.1 Past

  • STOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 135.71%, which is quite impressive.
  • STOK shows a strong growth in Revenue. In the last year, the Revenue has grown by 1128.17%.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.3%
Revenue 1Y (TTM)1128.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%117.25%

3.2 Future

  • STOK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.18% yearly.
  • The Revenue is expected to grow by 79.18% on average over the next years. This is a very strong growth
EPS Next Y111.38%
EPS Next 2Y-35.91%
EPS Next 3Y-15.57%
EPS Next 5Y15.18%
Revenue Next Year939.02%
Revenue Next 2Y35.9%
Revenue Next 3Y49.81%
Revenue Next 5Y79.18%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. STOK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 44.53, which means the current valuation is very expensive for STOK.
  • Based on the Price/Earnings ratio, STOK is valued cheaper than 90.37% of the companies in the same industry.
  • STOK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.54.
  • STOK is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 44.53
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of STOK indicates a rather cheap valuation: STOK is cheaper than 90.17% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, STOK is valued cheaper than 93.26% of the companies in the same industry.
Industry RankSector Rank
P/FCF 36.3
EV/EBITDA 52.21
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • STOK's earnings are expected to decrease with -15.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y-35.91%
EPS Next 3Y-15.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. STOK Dividend Analysis

5.1 Amount

  • No dividends for STOK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

STOK Fundamentals: All Metrics, Ratios and Statistics

STOKE THERAPEUTICS INC

NASDAQ:STOK (3/23/2026, 8:20:04 PM)

After market: 33.7 +0.3 (+0.9%)

33.4

-0.11 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11
Earnings (Next)05-11
Inst Owners123.18%
Inst Owner Change4.71%
Ins Owners3.99%
Ins Owner Change-8.86%
Market Cap1.91B
Revenue(TTM)205.63M
Net Income(TTM)41.05M
Analysts87.78
Price Target39.21 (17.4%)
Short Float %22.64%
Short Ratio16.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.64%
Min EPS beat(2)-12.12%
Max EPS beat(2)23.41%
EPS beat(4)3
Avg EPS beat(4)159.13%
Min EPS beat(4)-12.12%
Max EPS beat(4)558.67%
EPS beat(8)7
Avg EPS beat(8)85.57%
EPS beat(12)10
Avg EPS beat(12)60.58%
EPS beat(16)12
Avg EPS beat(16)28.75%
Revenue beat(2)2
Avg Revenue beat(2)60.62%
Min Revenue beat(2)52.02%
Max Revenue beat(2)69.22%
Revenue beat(4)4
Avg Revenue beat(4)553.32%
Min Revenue beat(4)52.02%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)289.38%
Revenue beat(12)10
Avg Revenue beat(12)187.93%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.54%
PT rev (3m)18.75%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)1.7%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)16.46%
Revenue NQ rev (1m)-8.34%
Revenue NQ rev (3m)1.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE 44.53
Fwd PE N/A
P/S 9.28
P/FCF 36.3
P/OCF 35.97
P/B 6.19
P/tB 6.19
EV/EBITDA 52.21
EPS(TTM)0.75
EY2.25%
EPS(NY)-3.1
Fwd EYN/A
FCF(TTM)0.92
FCFY2.76%
OCF(TTM)0.93
OCFY2.78%
SpS3.6
BVpS5.39
TBVpS5.39
PEG (NY)0.4
PEG (5Y)N/A
Graham Number9.54
Profitability
Industry RankSector Rank
ROA 11.39%
ROE 13.32%
ROCE 8.43%
ROIC 6.66%
ROICexc 30.2%
ROICexgc 30.2%
OM 13.06%
PM (TTM) 19.96%
GM N/A
FCFM 25.56%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 25.22%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 184.52%
Profit Quality 128.04%
Current Ratio 6.53
Quick Ratio 6.53
Altman-Z 21.89
F-Score8
WACC9.28%
ROIC/WACC0.72
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.3%
EPS Next Y111.38%
EPS Next 2Y-35.91%
EPS Next 3Y-15.57%
EPS Next 5Y15.18%
Revenue 1Y (TTM)1128.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%117.25%
Revenue Next Year939.02%
Revenue Next 2Y35.9%
Revenue Next 3Y49.81%
Revenue Next 5Y79.18%
EBIT growth 1Y122.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.24%
EBIT Next 3Y-15.58%
EBIT Next 5Y31.31%
FCF growth 1Y162.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y164.06%
OCF growth 3YN/A
OCF growth 5YN/A

STOKE THERAPEUTICS INC / STOK Fundamental Analysis FAQ

What is the fundamental rating for STOK stock?

ChartMill assigns a fundamental rating of 5 / 10 to STOK.


Can you provide the valuation status for STOKE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to STOKE THERAPEUTICS INC (STOK). This can be considered as Fairly Valued.


Can you provide the profitability details for STOKE THERAPEUTICS INC?

STOKE THERAPEUTICS INC (STOK) has a profitability rating of 4 / 10.


What is the expected EPS growth for STOKE THERAPEUTICS INC (STOK) stock?

The Earnings per Share (EPS) of STOKE THERAPEUTICS INC (STOK) is expected to grow by 111.38% in the next year.